ID: h-fe0badfd2d
Hypothesis
Patients with OSA or high nocturnal arousal burden may require higher trazodone doses, but OSA is better treated as a covariate than a lead disease-modification hypothesis
OSA-related arousal burden could raise the dose needed for any sleep-mediated neuroprotective effect, perhaps toward 100 mg rather than 50 mg.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 3 oppose
🧪 Overview
OSA-related arousal burden could raise the dose needed for any sleep-mediated neuroprotective effect, perhaps toward 100 mg rather than 50 mg. This is the least supported development hypothesis because it depends on a long causal chain from OSA physiology to biomarker benefit in dementia and is heavily confounded by standard OSA care and endotype heterogeneity.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Obstructive Sleep Apnea<br/>Nocturnal Arousal Burden"]
B["HTR2A Signaling<br/>Serotonin Receptor 2A"]
C["HRH1 Histamine Receptor<br/>Mediator Release"]
D["Sleep Architecture<br/>Disruption"]
E["Higher Trazodone<br/>Dose Requirement"]
F["REM Suppression<br/>Sleep Quality Impact"]
G["Precision Dosing<br/>via HTR2A/HRH1 Stratification"]
A --> B
A --> C
B --> D
C --> D
D --> E
E --> F
G -.->|"optimizes"| E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports3 contradicts
Supports
Maprotiline restores ER homeostasis and rescues neurodegeneration via Histamine Receptor H1 inhibition in retinal ganglion cells.
Supports
Histamine H1 Receptors in Neural Stem Cells Are Required for the Promotion of Neurogenesis Conferred by H3 Receptor Antagonism following Traumatic Brain Injury.
Supports
Clemastine promotes recovery of neural function and suppresses neuronal apoptosis by restoring balance of pro-inflammatory mediators in an experimental model of intracerebral hemorrhage.
Contradicts
One OSA study reduced AHI without significant arousal-threshold change, weakening the proposed mechanism.
Contradicts
CPAP adherence, anatomy, and OSA endotype likely dominate any trazodone effect, limiting strategic value as a lead hypothesis.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HTR2A;
No curated PDB or AlphaFold mapping for HTR2A; yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for HTR2A; HRH1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HTR2A; HRH1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.2%
Volatility
High
0.1287
Events (7d)
2
Price History
▲5.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF older adults with high nocturnal arousal burden (>15 arousals/hour on polysomnography) receive 100 mg trazodone versus 50 mg trazodone for 12 weeks, THEN the high-dose group will show superior impr | Sleep efficiency increases by ≥8% in high-dose group; CSF NfL decreases by ≥15% relative to low-dose group within 3 months | — no observation — | pending | 0.25 |
| IF OSA status is added as a stratification variable to a cohort receiving trazodone 50 mg nightly for 8 weeks, THEN patients without OSA will exhibit significantly greater improvement in next-morning | Non-OSA group shows ≥20% greater improvement in DSST scores compared to OSA group at 8 weeks | — no observation — | pending | 0.20 |
🔮 Falsifiable Predictions (2)
pendingconf 25%
IF older adults with high nocturnal arousal burden (>15 arousals/hour on polysomnography) receive 100 mg trazodone versus 50 mg trazodone for 12 weeks, THEN the high-dose group will show superior improvement in sleep efficiency (≥8% absolute increase) and CSF neurofilament light chain levels will de
Predicted outcome: Sleep efficiency increases by ≥8% in high-dose group; CSF NfL decreases by ≥15% relative to low-dose group within 3 months
Falsification: No significant difference in sleep efficiency between 50 mg and 100 mg doses (p > 0.05) OR CSF NfL levels increase or remain stable in high-dose arm
pendingconf 20%
IF OSA status is added as a stratification variable to a cohort receiving trazodone 50 mg nightly for 8 weeks, THEN patients without OSA will exhibit significantly greater improvement in next-morning cognition (Digit Symbol Substitution Test) than patients with OSA, controlling for age, BMI, and bas
Predicted outcome: Non-OSA group shows ≥20% greater improvement in DSST scores compared to OSA group at 8 weeks
Falsification: No significant difference in cognitive improvement between OSA and non-OSA groups (p > 0.05) OR OSA patients show equal or greater DSST improvement compared to non-OSA patients
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.